{
    "nct_id": "NCT03730012",
    "official_title": "Phase 1/2 Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)",
    "inclusion_criteria": "* Subject is considered an adult according to local regulation at the time of signing informed consent form (ICF).\n* Subject has defined AML by the World Health Organization (WHO) criteria (2017) and fulfills one of the following:\n\n  * Refractory to at least 1 cycle of induction chemotherapy\n  * Relapsed after achieving remission with a prior therapy\n* Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment.\n* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at screening.\n* Subject must meet the following criteria as indicated on the clinical laboratory tests:\n\n  * Serum Aspartate aminotransferase (AST) and Alanine Aminotransferease (ALT) ≤ 2.5 x upper limit of normal (ULN)\n  * Serum total bilirubin (TBL) ≤ 1.5 x ULN\n  * Serum creatinine ≤ 1.5 x ULN or an estimated glomerular filtration rate of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.\n* Subject is suitable for oral administration of study drug.\n* A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies:\n\n  * Not a woman of childbearing potential (WOCBP) OR\n  * WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration.\n* Female subject must agree not to breastfeed starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.\n* Female subject must not donate ova starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.\n* A male subject must not donate sperm starting at screening and throughout the treatment period, and for at least 120 days after the final study drug administration.\n* A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period, and for at least 120 days after the final study drug administration.\n* Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for 120 days after the final study drug administration.\n* Subject agrees not to participate in another investigational study while on treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subject was diagnosed as acute promyelocytic leukemia.\n* Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).\n* Subject has AML secondary to prior chemotherapy for other neoplasms (except for myelodysplastic syndrome).\n* Subject has clinically active central nervous system leukemia.\n* Subject has uncontrolled or significant cardiovascular disease, including:\n\n  * A myocardial infarction within 12 months\n  * Uncontrolled angina within 6 months\n  * History of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes) or any history of arrhythmia\n  * Uncontrolled hypertension\n* Subject has baseline left ventricular ejection fraction that is ≥ 45%.\n* Subject has mean triplicate Fridericia-corrected QT interval (QTcF) > 450 ms at Screening based on central reading.\n* Subject has congenital or acquired Long QT Syndrome at screening.\n* Subject has hypokalemia and/or hypomagnesemia at screening.\n* Subject has been diagnosed with another malignancy that requires concurrent treatment or hepatic malignancy regardless of the need for treatment.\n* Subject has clinically significant coagulation abnormality unless secondary to AML.\n* Subject is receiving or plans to receive concomitant chemotherapy or immunotherapy.\n* Subject has had major surgery within 4 weeks prior to the first study dose.\n* Subject has radiation therapy within 4 weeks prior to the first study dose.\n* Subject requires treatment with concomitant drugs that are strong inducers of Cytochrome P450 (CYP3A).\n* Subject has known pulmonary disease with diffusion capacity of lung for carbon monoxide ≤ 65%, forced expiratory volume in the first second (FEV1) ≤ 65%, dyspnea at rest or requiring oxygen or any pleural neoplasm.\n* Subject with systemic fungal, bacterial, viral or other uncontrolled infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. Subject needs to be off pressors and have negative blood cultures for 48 hours.\n* Subject has not recovered from any prior therapy related toxicities.\n* Subject is known to have human immunodeficiency virus infection.\n* Subject has active hepatitis B or C or other active hepatic disorder.\n* Subject has previously been treated with gilteritinib, quizartinib or crenolanib (will only apply to subjects enrolled in the phase 2 portion of the study).\n* Subject has active clinically significant graft-versus-host disease (GVHD) or is on treatment with systemic corticosteroids for GVHD.\n* Subject has relapsed after allogeneic hematopoietic stem cell transplant (HCST).\n* Subject has an active autoimmune disorder that makes the subject unsuitable for study treatment or participation.\n* Subject has any condition that makes the subject unsuitable for study participation.",
    "miscellaneous_criteria": ""
}